Skip to main content
. 2021 Mar 19;100(5):1181–1194. doi: 10.1007/s00277-021-04465-4

Fig. 1.

Fig. 1

Kaplan–Meier plots of overall survival in the a overall population, b de novo AML subgroup, c secondary AML subgroup, and d overall population censoring for patients receiving follow-up HMAs. GLAS, glasdegib; mo, months; mOS, median overall survival